Janux Therapeutics (JANX) Return on Capital Employed (2021 - 2025)
Janux Therapeutics (JANX) has disclosed Return on Capital Employed for 5 consecutive years, with 0.16% as the latest value for Q4 2025.
- Quarterly Return on Capital Employed fell 4.0% to 0.16% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.16% through Dec 2025, down 4.0% year-over-year, with the annual reading at 0.16% for FY2025, 2.0% down from the prior year.
- Return on Capital Employed for Q4 2025 was 0.16% at Janux Therapeutics, down from 0.14% in the prior quarter.
- The five-year high for Return on Capital Employed was 0.06% in Q3 2021, with the low at 0.23% in Q2 2023.
- Average Return on Capital Employed over 5 years is 0.15%, with a median of 0.14% recorded in 2025.
- The sharpest move saw Return on Capital Employed fell -12bps in 2022, then rose 14bps in 2024.
- Over 5 years, Return on Capital Employed stood at 0.09% in 2021, then crashed by -115bps to 0.19% in 2022, then fell by -4bps to 0.2% in 2023, then soared by 42bps to 0.11% in 2024, then crashed by -39bps to 0.16% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.16%, 0.14%, and 0.14% for Q4 2025, Q3 2025, and Q2 2025 respectively.